Literature DB >> 22750491

Why has butyrylcholinesterase been retained? Structural and functional diversification in a duplicated gene.

Glynis Johnson1, Samuel W Moore.   

Abstract

While acetylcholinesterase (EC 3.1.1.7) has a clearly defined role in neurotransmission, the functions of its sister enzyme butyrylcholinesterase (EC 3.1.1.8) are more obscure. Numerous mutations, many inactivating, are observed in the human butyrylcholinesterase gene, and the butyrylcholinesterase knockout mouse has an essentially normal phenotype, suggesting that the enzyme may be redundant. Yet the gene has survived for many millions of years since the duplication of an ancestral acetylcholinesterase early in vertebrate evolution. In this paper, we ask the questions: why has butyrylcholinesterase been retained, and why are inactivating mutations apparently tolerated? Butyrylcholinesterase has diverged both structurally and in terms of tissue and cellular expression patterns from acetylcholinesterase. Butyrylcholinesterase-like activity and enzymes have arisen a number of times in the animal kingdom, suggesting the usefulness of such enzymes. Analysis of the published literature suggests that butyrylcholinesterase has specific roles in detoxification as well as in neurotransmission, both in the brain, where it appears to control certain areas and functions, and in the neuromuscular junction, where its function appears to complement that of acetylcholinesterase. An analysis of the mutations in human butyrylcholinesterase and their relation to the enzyme's structure is shown. In conclusion, it appears that the structure of butyrylcholinesterase's catalytic apparatus is a compromise between the apparently conflicting selective demands of a more generalised detoxifier and the necessity for maintaining high catalytic efficiency. It is also possible that the tolerance of mutation in human butyrylcholinesterase is a consequence of the detoxification function. Butyrylcholinesterase appears to be a good example of a gene that has survived by subfunctionalisation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22750491     DOI: 10.1016/j.neuint.2012.06.016

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  20 in total

1.  Tracking the origin and divergence of cholinesterases and neuroligins: the evolution of synaptic proteins.

Authors:  Nicolas Lenfant; Thierry Hotelier; Yves Bourne; Pascale Marchot; Arnaud Chatonnet
Journal:  J Mol Neurosci       Date:  2014-01-05       Impact factor: 3.444

2.  Cryo-EM structure of the native butyrylcholinesterase tetramer reveals a dimer of dimers stabilized by a superhelical assembly.

Authors:  Miguel Ricardo Leung; Laura S van Bezouwen; Lawrence M Schopfer; Joel L Sussman; Israel Silman; Oksana Lockridge; Tzviya Zeev-Ben-Mordehai
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-11       Impact factor: 11.205

3.  Black and non-black population: investigation of the difference in butyrylcholinesterase activity in a healthy population in Salvador, Bahia.

Authors:  Jucelino Nery da Conceição Filho; Iris Campos Dos Santos; Davi Pereira de Jesus Gonçalves; Junia Raquel Dutra Ferreira; Ana Leonor Pardo Campos Godoy
Journal:  Ir J Med Sci       Date:  2022-07-06       Impact factor: 1.568

4.  Butyrylcholinesterase predicts cardiac mortality in young patients with acute coronary syndrome.

Authors:  Patrick Sulzgruber; Lorenz Koller; Thomas Reiberger; Feras El-Hamid; Stefan Forster; David-Jonas Rothgerber; Georg Goliasch; Johann Wojta; Alexander Niessner
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

5.  Influence of the Melissa officinalis Leaf Extract on Long-Term Memory in Scopolamine Animal Model with Assessment of Mechanism of Action.

Authors:  Marcin Ozarowski; Przemyslaw L Mikolajczak; Anna Piasecka; Piotr Kachlicki; Radoslaw Kujawski; Anna Bogacz; Joanna Bartkowiak-Wieczorek; Michal Szulc; Ewa Kaminska; Malgorzata Kujawska; Jadwiga Jodynis-Liebert; Agnieszka Gryszczynska; Bogna Opala; Zdzislaw Lowicki; Agnieszka Seremak-Mrozikiewicz; Boguslaw Czerny
Journal:  Evid Based Complement Alternat Med       Date:  2016-04-28       Impact factor: 2.629

6.  Butyryl-cholinesterase deficiency: A case report of delayed recovery after general anaesthesia.

Authors:  Ahmed Al-Emam
Journal:  Toxicol Rep       Date:  2021-06-17

7.  Reduced vagal control of the heart in high-fat diet mice: a potential role of increased butyrylcholinesterase.

Authors:  Sigurd Hartnett; Hongbo Gao; Sabrina Schnack; Yifan Li
Journal:  Physiol Rep       Date:  2015-11

8.  New Insights into Butyrylcholinesterase Activity Assay: Serum Dilution Factor as a Crucial Parameter.

Authors:  Joanna Jońca; Monika Żuk; Bartosz Wasąg; Anna Janaszak-Jasiecka; Krzysztof Lewandowski; Bartosz Wielgomas; Krzysztof Waleron; Jacek Jasiecki
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

9.  Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.

Authors:  Herve Delacour; Sofya Lushchekina; Isabelle Mabboux; Aurore Bousquet; Franck Ceppa; Lawrence M Schopfer; Oksana Lockridge; Patrick Masson
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

10.  Characterization of placental cholinesterases and activity induction associated to environmental organophosphate exposure.

Authors:  S Sánchez; B Vera; C Montagna; G Magnarelli
Journal:  Toxicol Rep       Date:  2014-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.